Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ad Astra Diagnostics
Columbia, Missouri, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Ad Astra Diagnostics' QScout Lab and QScout CBC platform is designed for rapid, point-of-care complete blood count testing, including measurement of immature granulocytes as an early marker of sepsis. QScout CBC is not FDA cleared and not for sale. QScout RLD, an initial test measuring immature granulocytes at point-of-care, is FDA cleared.
- Therapeutic areas
- OncologyHematologyInfectious Diseases
- Modalities
- Device
- Industry
- Pathology
Beyond the preview
Go deeper on Ad Astra Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad Astra Diagnostics.